Investment Thesis
Werewolf Therapeutics is a pre-commercial stage pharmaceutical company with zero revenue, negative operating cash flow of $10.6M annually, and a debt-to-equity ratio of 2.63x that cannot be serviced from operations. While the company maintains $46.5M in cash reserves (~4.5 years of runway at current burn rate), the combination of negative profitability, substantial debt burden, and lack of any commercial operations signals high financial distress risk.
Strengths
- Adequate cash reserves ($46.5M) provide near-term operational runway
- Current liquidity ratio of 1.27x maintains minimal short-term solvency
- Nasdaq listing indicates past regulatory compliance for public markets
Risks
- Zero revenue indicates no commercial product traction or market validation
- Negative operating cash flow of $10.6M annually with no offsetting revenue
- Debt-to-equity ratio of 2.63x with negative interest coverage (-9.7x) creates unsustainable leverage
- High risk of equity dilution or debt restructuring as cash reserves deplete
- ROE of -110.9% and ROA of -23.3% demonstrate value destruction
- Pre-commercial stage with unproven clinical pipeline execution risk
Key Metrics to Watch
- Cash burn rate and remaining runway (currently ~4.5 years at $10.6M annual burn)
- Clinical trial progress and regulatory milestones for pipeline programs
- Debt refinancing events and covenant compliance
- Operating expenses trend and cash conservation efforts
Financial Metrics
Revenue
N/A
Net Income
-13.5M
EPS (Diluted)
$-0.28
Free Cash Flow
-10.6M
Total Assets
58.0M
Cash
46.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-110.9%
ROA
-23.3%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
1.27x
Quick Ratio
1.27x
Debt/Equity
2.63x
Debt/Assets
79.0%
Interest Coverage
-9.70x
Long-term Debt
32.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T09:18:20.201969 |
Data as of: 2026-03-31 |
Powered by Claude AI